Literature DB >> 12056037

[MHC-class I expression on prostate carcinoma and modulation by IFN-gamma].

Michio Naoe1, Yoshiko Marumoto, Keiichiro Aoki, Takashi Fukagai, Yoshio Ogawa, Ryoutaro Ishizaki, Yoshizo Nakagami, Hideki Yoshida, Michel Ballo.   

Abstract

OBJECTIVES: In this study, we investigated MHC-class I expression on both prostate cancer and normal prostate and compared those data with the number of CD8+ lymphocyte. Secondary, we investigated effect of IFN-gamma to the MHC-class I expression on prostate carcinoma.
MATERIALS AND METHODS: Twenty cryo-preserved benign prostate samples (Seven normal prostates and five benign prostatic hypertrophy samples.) and fifteen prostate carcinoma samples were used for immunohistochemistry of CD8 and MHC-class I. Eleven fresh single cell suspensions of prostate carcinoma were used for IFN-gamma study. After 24 hours IFN-gamma stimulation, MHC-I expression was measured by FACs analysis.
RESULTS: Interestingly, significant correlation was observed between MHC-class I expression and the CD8+ lymphocyte infiltrate (r = 0.705, P < 0.0001). After 24 hrs IFN-gamma stimulation, MHC-class I expression was up-regulated in all samples (p < 0.05).
CONCLUSION: Reduced expression of MHC-class I was thought as one of the factor which is related to the reduced degree of TILs (tumor infiltratig lymphocytes) in prostate cancer. IFN-gamma which is secreted mainly from CTL (cytotoxic T lymphocyte) might increase the degree of TIL through up-regulated MHC-class I.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12056037     DOI: 10.5980/jpnjurol1989.93.532

Source DB:  PubMed          Journal:  Nihon Hinyokika Gakkai Zasshi        ISSN: 0021-5287


  2 in total

1.  Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes.

Authors:  Ilsa M Coleman; Jeffrey A Kiefer; Lisha G Brown; Tiffany E Pitts; Peter S Nelson; Kristen D Brubaker; Robert L Vessella; Eva Corey
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

Review 2.  Immunotherapy in prostate cancer: new horizon of hurdles and hopes.

Authors:  Igor Tsaur; Maximilian P Brandt; Eva Juengel; Cécile Manceau; Guillaume Ploussard
Journal:  World J Urol       Date:  2020-10-26       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.